 |
|
Therapies for Disorders of the Neuromuscular Junction
Arch Neurol. 2002;59:739-742.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
DURING THE past 3 decades, the therapeutic options for patients with
neuromuscular transmission disorders have greatly increased. However, debate
continues on the best approach to both short-term and long-term management.
Although therapies have decreased mortality, the clinical course continues
to present problems for most patients. No mode of therapy has been proven
to be clearly superior; therefore, the choice of therapy should focus on the
individual patient.
Several factors determine the type of therapy that is most appropriate
for a given patient. Ideally, the therapy should have minimal adverse effects,
be easy to use, and be inexpensive. Therapeutic decisions in an acute setting
are based on the patient's rate of disease progression, distribution of weakness,
and confounding medical factors. Long-term therapeutic decisions are based
on the patient's age, sex, and the presence of other diseases. The presence
or absence of thymoma in patients with myasthenia gravis also influences the
immediate . . . [Full Text of this Article] MYASTHENIA GRAVIS THERAPY
Symptomatic Therapy Cholinesterase Inhibitors Plasmapheresis Immunotherapy Thymectomy Corticosteroids Azathioprine Cyclosporine Cyclophosphamide IVIG Mycophenolate Mofetil
SPECIAL CONSIDERATIONS
Ocular Myasthenia
Pregnancy Lambert-Eaton Myasthenic Syndrome
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(5):878-880.
FULL TEXT
|
